Swedish Orphan Biovitrum Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St

Swedish Orphan Biovitrum (STO:SOBI) Full Year 2024 Results

Key Financial Results

  • Revenue: kr26.0b (up 18% from FY 2023).
  • Net income: kr3.89b (up 61% from FY 2023).
  • Profit margin: 15% (up from 11% in FY 2023). The increase in margin was driven by higher revenue.
  • EPS: kr11.37 (up from kr7.47 in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

SOBI Products In Clinical Trials

  • Phase II: 2.
  • Phase III: 2.

SOBI Post-Clinical Trial Products

  • Pre-registration: 5.
OM:SOBI Revenue and Expenses Breakdown April 3rd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Swedish Orphan Biovitrum EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.3%.

The primary driver behind last 12 months revenue was the Hematology segment contributing a total revenue of kr16.4b (63% of total revenue). The largest operating expense was General & Administrative costs, amounting to kr11.0b (67% of total expenses). Explore how SOBI's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are down 1.7% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Swedish Orphan Biovitrum's balance sheet.

Valuation is complex, but we're here to simplify it.

Discover if Swedish Orphan Biovitrum might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.